IXICO (LSE:IXI) 5-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is IXICO 5-Year EBITDA Growth Rate?

IXICO's EBITDA per Share for the six months ended in Mar. 2024 was £-0.03.

During the past 12 months, IXICO's average EBITDA Per Share Growth Rate was -433.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of IXICO was 61.00% per year. The lowest was -70.90% per year. And the median was 8.60% per year.

Competitive Comparison of IXICO's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, IXICO's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IXICO's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IXICO's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where IXICO's 5-Year EBITDA Growth Rate falls into.

IXICO 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

IXICO (LSE:IXI) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

IXICO 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of IXICO's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

IXICO (LSE:IXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

PHYOF:USA

Address

15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN

Website

https://www.ixico.com

IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (LSE:IXI) Headlines

No Headlines